BIAFbioAffinity Technologies Inc. Common Stock
0.4000USD-2.20%Mkt Cap: 3.24M $P/E: —3d ago
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United Sta…
Industry Peers
Diagnostics & Research$232.67BUSDP/E 33.9
$153.85BUSDP/E 39.0
$47.21BUSDP/E 38.3
$47.86BUSD
$44.91BUSDP/E 31.9
$43.93BUSDP/E 39.1
$42.77BUSDP/E 32.3
$40.32BUSDP/E 103.5
$33.13BUSDP/E 41.0
$27.96BUSDP/E 31.5
$27.28BUSDP/E 27.8
$26.97BUSDP/E 26.0
$22.91BUSD
$17.33BUSDP/E 36.4
$13.65BUSDP/E 25.3
$14.09BUSD
$13.92BUSDP/E 59.7
$13.29BUSDP/E 269.1
$9.55BUSDP/E 19.1
$9.13BUSD
| Headline | Source | Time |
|---|---|---|
Older | ||
 bioAffinity Technologies Signs Nationwide Federal Healthcare Distribution Agreement for CyPath Lung bioAffinity Technologies, Inc. (NASDAQ:BIAF) has signed a nationwide federal healthcare distribution agreement with AvMEDICAL for CyPath Lung, giving the lung cancer diagnostic access to an established government sales and procurement network. | ||
 BIAF vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now? bioAffinity and Biodesix pursue different cancer diagnostics strategies, but which oncology stock offers better long-term upside? Let's dive in. | ||